Home / Health / FDA approves new weight loss drug First time since 2014

FDA approves new weight loss drug First time since 2014

The Food and Drug Administration (FDA) has approved a diet pill for overweight or obese adults. This is the first approval since 2014. Wegovy is a subcutaneous drug intended for use in addition to Reduced calorie diet and increased exercise

“Today’s approval gives obese or overweight adults a choice,” said John Sharretts, MD, deputy director of the Division of Diabetes, Lipid Disorders, and Obesity at the FDA’s Center for Drug Evaluation and Research. in a useful new treatment to integrate into a weight management program. said in a press release “The FDA remains committed to facilitating the development and approval of additional safe and effective treatments for obese or overweight adults.”


The drug works by mimicking the hormone peptide-1. similar to glucagon which targets areas of the brain that help control appetite and eating The FDA warns that it should not be used with other semalutide-containing products, other GLP-1 receptor agonists, or other weight loss products, including herbal products. Over-the-counter or prescription drugs

Eating Fresh Fruit Reduces the Risk of Type 2 Diabetes, Study Claims

The dosage is gradually increased over 16 to 20 weeks to 2.4 mg once a week to reduce gastrointestinal side effects.

The approval came after four successful 68-week trials involving more than 2,600 patients. Participants saw a 6.2 percent reduction in their initial body weight compared to the other 1,500 patients who received placebo.

The most common side effects reported include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, tiredness, indigestion, dizziness, stomach gas, enteritis, hypoglycemia in type 2 diabetes, and others.


The FDA says about 70% of American adults are obese. which is linked to major causes of death such as heart disease, stroke and diabetes Including an increased risk for some cancers, a 5% to 10% weight loss from diet and exercise was associated with a reduced risk of cardiovascular disease in this population.

Source link